Duerr, Michael http://orcid.org/0000-0003-1432-421X
Schrezenmeier, Eva V.
Lehner, Lukas J.
Bergfeld, Léon
Glander, Petra
Marticorena Garcia, Stephan R.
Althoff, Christian E.
Sack, Ingolf
Brakemeier, Susanne
Eckardt, Kai-Uwe
Budde, Klemens
Halleck, Fabian
Funding for this research was provided by:
Bristol-Myers Squibb GmbH & Co. KGaA
Article History
Received: 10 October 2018
Accepted: 17 January 2019
First Online: 4 February 2019
Ethics approval and consent to participate
: All patients provided written informed consent. The study protocols were conducted in compliance with German law and approved by the independent ethics committee at the “Landesamt für Gesundheit und Soziales” of the state Berlin (approval number: 15/0446EK15) and the Federal Institute for Drugs and Medical Devices (approval number: 4040892).All procedures followed in the trials were in accordance with the Declaration of Helsinki, the International Conference on Harmonization and Good Clinical Practice guidelines.
: Not applicable.
: Michael Duerr received a travel grant and speakers honoraria from BMS, Novartis, Roche and Astellas.Eva V. Schrezenmeier has no conflict of interest to declare.Lukas L. Lehner has no conflict of interest to declare.Leon Bergfeld has no conflict of interest to declare.Petra Glander has no conflict of interest to declare.Stephan R. Marticorena has no conflict of interest to declare.Christian E. Althoff has no conflict of interest to declare.Ingolf Sack has no conflict of interest to declare.Susanne Brakemeier has no conflict of interest to declare.Kai-Uwe Eckardt has no conflict of interest to declare.Klemens Budde has received research funds and/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Shire, Siemens, and Veloxis Pharma.Fabian Hallck has no conflict of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.